United Therapeutics (NASDAQ:UTHR) Stock Bumped Up to “Strong Sell” by The Goldman Sachs Group

The Goldman Sachs Group upgraded shares of United Therapeutics (NASDAQ:UTHR) to a strong sell rating in a research report released on Thursday morning,Zacks reports.

Other equities analysts have also issued research reports about the stock. Morgan Stanley set a $515.00 price target on shares of United Therapeutics in a research report on Thursday, August 6th. JPMorgan Chase & Co. raised their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Weiss Ratings downgraded United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, August 27th. Royal Bank Of Canada decreased their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Finally, Bank of America decreased their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Eleven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $621.00.

United Therapeutics Price Performance

UTHR opened at $472.21 on Thursday. United Therapeutics has a fifty-two week low of $409.07 and a fifty-two week high of $609.35. The firm has a market capitalization of $20.25 billion, a P/E ratio of 16.89, a PEG ratio of 2.49 and a beta of 0.56. The company’s 50-day moving average is $512.06 and its 200 day moving average is $540.50.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping the consensus estimate of $6.86 by $0.41. The firm had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same quarter last year, the firm earned $6.41 EPS. On average, equities research analysts expect that United Therapeutics will post 26.21 earnings per share for the current year.

Insider Activity

In other United Therapeutics news, CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $545.80, for a total value of $5,185,100.00. Following the completion of the sale, the chief executive officer owned 40,513 shares of the company’s stock, valued at $22,111,995.40. This represents a 19.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In the last three months, insiders sold 355,553 shares of company stock valued at $184,183,266. 8.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of UTHR. QRG Capital Management Inc. boosted its holdings in United Therapeutics by 3.5% in the second quarter. QRG Capital Management Inc. now owns 3,476 shares of the biotechnology company’s stock valued at $1,883,000 after acquiring an additional 116 shares in the last quarter. Envestnet Portfolio Solutions Inc. boosted its stake in shares of United Therapeutics by 1.8% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 3,445 shares of the biotechnology company’s stock valued at $1,867,000 after purchasing an additional 60 shares in the last quarter. Andra AP fonden increased its position in shares of United Therapeutics by 33.5% during the second quarter. Andra AP fonden now owns 34,904 shares of the biotechnology company’s stock valued at $18,912,000 after buying an additional 8,760 shares during the period. Security National Bank of SO Dak bought a new position in United Therapeutics in the second quarter worth about $179,000. Finally, Talon Private Wealth LLC lifted its holdings in United Therapeutics by 31.8% in the second quarter. Talon Private Wealth LLC now owns 6,753 shares of the biotechnology company’s stock worth $3,659,000 after buying an additional 1,630 shares during the period. Institutional investors own 94.08% of the company’s stock.

Key Stories Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics is deploying the remainder of its $2 billion share-repurchase authorization through an accelerated share repurchase. A lower share count could support earnings per share and provide some demand for the stock, although investors may continue to debate the capital-allocation decision. United Therapeutics: Strong Catalyst Flow Bodes Well For Near-Term Growth
• Neutral Sentiment: The company’s latest quarterly results exceeded EPS expectations, with $7.27 in adjusted earnings versus an estimated $6.86. However, revenue of $783.3 million missed estimates and declined 1.9% year over year, reinforcing investor focus on whether newer therapies can offset pressure on the established business.
• Negative Sentiment: Goldman Sachs initiated coverage of UTHR with a Sell rating and a $321 price target. The analyst argued that the stock’s premium valuation is inconsistent with a shrinking core business and a challenging launch outlook for Tyvaso and Jenraldi. United Therapeutics downgraded to Sell
• Negative Sentiment: The Goldman report cited reimbursement and payer risks, generic competition, and uncertainty over real-world adoption of Jenraldi. Investors are also watching whether nebulized Tyvaso can secure broader coverage, which could affect future revenue growth. United Therapeutics slips as new Sell rating pressures shares
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares for approximately $4.7 million, reducing her holdings by 2.84%. The transaction may weigh on sentiment, particularly alongside reported insider selling without recent purchases, though it may also reflect routine personal financial planning. SEC insider transaction filing

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.